TScan Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDTScan Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is weak (RS Rating: 27), showing significant lag compared to the market leaders. Earnings growth of 15% provides fundamental context to the price action. Investors should exercise caution due to high volatility (87% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.94 | +13.56% | ABOVE |
| 50 SMA | $1.06 | +0.93% | ABOVE |
| 100 SMA | $1.06 | +1.02% | ABOVE |
| 150 SMA | $1.06 | +1.29% | ABOVE |
| 200 SMA | $1.23 | -13.04% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TCRX in an uptrend right now?
TCRX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is TCRX overbought or oversold?
TCRX's RSI (14) is 51. The stock is in neutral territory, neither overbought nor oversold.
Is TCRX outperforming the market?
TCRX has a Relative Strength (RS) Rating of 27 out of 99. TCRX is currently lagging the broader market.
Where is TCRX in its 52-week range?
TCRX is trading at $1.07, which is 42% of its 52-week high ($2.57) and 14% above its 52-week low ($0.83).
How volatile is TCRX?
TCRX has a Beta of 2.05 and 52-week volatility of 87%. It's more volatile than the S&P 500 - expect bigger swings.